Childhood cancer survivors at risk for cardiac events

Childhood cancer survivors at risk for cardiac events

(HealthDay) -- Childhood cancer survivors (CCSs) treated with anthracyclines and/or cardiac irradiation have a higher risk of developing symptomatic cardiac events (CEs) in the long term, according to a study published online April 2 in the Journal of Clinical Oncology.

Helena J. van der Pal, M.D., Ph.D., of the Emma Children's Hospital/Academic Medical Center in Amsterdam, and colleagues evaluated the long-term risk for symptomatic CEs in a hospital-based cohort of 1,362 five-year CCSs who were diagnosed between 1966 and 1996.

The researchers identified 50 CEs, including 27 cases of , in 42 survivors, which occurred at a median of 27.1 years of age. The 30-year cause-specific cumulative incidence of CEs was 12.6 percent for those who were treated with anthracyclines and cardiac irradiation, 7.3 percent for those treated with anthracycline, and 4 percent for those treated with cardiac irradiation, which marked an increase compared with other treatments. Factors associated with developing a CE included the dose of anthracycline or cardiac irradiation, combination of these treatments, and .

"CCSs have a high risk of developing symptomatic CEs at an early age," the authors write. "Survivors treated with both anthracyclines and radiotherapy have the highest risk; after 30 years, one in eight will develop severe heart disease. The use of potentially cardiotoxic treatments should be reconsidered for high-risk groups, and frequent follow-up for high-risk survivors is needed."

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Long-term cardiac effects for childhood cancer survivors

date Mar 07, 2012

(HealthDay) -- Regardless of exposure to cardiotoxic cancer therapies, survivors of childhood cancers display cardiovascular abnormalities and have markers of increased systemic inflammation and atherosclerotic ...

Recommended for you

1950s drug is future heart treatment

date 11 hours ago

Oxford University researchers have found a promising future treatment for heart disease, going back to a drug first developed in 1950.

Time is muscle in acute heart failure

date 20 hours ago

Urgent diagnosis and treatment in acute heart failure has been emphasised for the first time in joint recommendations published today in European Heart Journal.

Common mutation linked to heart disease

date May 20, 2015

A common mutation in a gene that regulates cholesterol levels may raise the risk of heart disease in carriers, according to a new UConn Health study.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.